Some OVs are already approved for clinical use, such as Talimogene laherparepvec (T-VEC) for melanoma, a genetically modified granulocyte–macrophage colony-stimulating factor (GM-CSF)-expressing herpes simplex virus (HSV). Here, CSF2 is linked to melanoma.